515 related articles for article (PubMed ID: 29127681)
1. Reactivation of Fetal Hemoglobin for Treating β-Thalassemia and Sickle Cell Disease.
Cui S; Engel JD
Adv Exp Med Biol; 2017; 1013():177-202. PubMed ID: 29127681
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological Induction of Human Fetal Globin Gene in Hydroxyurea-Resistant Primary Adult Erythroid Cells.
Chou YC; Chen RL; Lai ZS; Song JS; Chao YS; Shen CK
Mol Cell Biol; 2015 Jul; 35(14):2541-53. PubMed ID: 25986606
[TBL] [Abstract][Full Text] [Related]
3. Bach1 inhibitor HPP-D mediates γ-globin gene activation in sickle erythroid progenitors.
Palani CD; Zhu X; Alagar M; Attucks OC; Pace BS
Blood Cells Mol Dis; 2024 Jan; 104():102792. PubMed ID: 37633023
[TBL] [Abstract][Full Text] [Related]
4. Identification of novel γ-globin inducers among all potential erythroid druggable targets.
Yu L; Myers G; Schneider E; Wang Y; Mathews R; Lim KC; Siemieniak D; Tang V; Ginsburg D; Balbin-Cuesta G; Singh SA; Phuwakanjana P; Jearawiriyapaisarn N; Khoriaty R; Engel JD
Blood Adv; 2022 Jun; 6(11):3280-3285. PubMed ID: 35240686
[TBL] [Abstract][Full Text] [Related]
5. Genetic Basis and Genetic Modifiers of β-Thalassemia and Sickle Cell Disease.
Thein SL
Adv Exp Med Biol; 2017; 1013():27-57. PubMed ID: 29127676
[TBL] [Abstract][Full Text] [Related]
6. A genome-editing strategy to treat β-hemoglobinopathies that recapitulates a mutation associated with a benign genetic condition.
Traxler EA; Yao Y; Wang YD; Woodard KJ; Kurita R; Nakamura Y; Hughes JR; Hardison RC; Blobel GA; Li C; Weiss MJ
Nat Med; 2016 Sep; 22(9):987-90. PubMed ID: 27525524
[TBL] [Abstract][Full Text] [Related]
7. Chemical Inhibition of Histone Deacetylases 1 and 2 Induces Fetal Hemoglobin through Activation of GATA2.
Shearstone JR; Golonzhka O; Chonkar A; Tamang D; van Duzer JH; Jones SS; Jarpe MB
PLoS One; 2016; 11(4):e0153767. PubMed ID: 27073918
[TBL] [Abstract][Full Text] [Related]
8. Quantification of HBG mRNA in primary erythroid cultures: prediction of the response to hydroxyurea in sickle cell and beta-thalassemia.
Pecoraro A; Rigano P; Troia A; Calzolari R; Scazzone C; Maggio A; Steinberg MH; Di Marzo R
Eur J Haematol; 2014 Jan; 92(1):66-72. PubMed ID: 24112139
[TBL] [Abstract][Full Text] [Related]
9. Potent and orally active purine-based fetal hemoglobin inducers for treating β-thalassemia and sickle cell disease.
Lai ZS; Yeh TK; Chou YC; Hsu T; Lu CT; Kung FC; Hsieh MY; Lin CH; Chen CT; James Shen CK; Jiaang WT
Eur J Med Chem; 2021 Jan; 209():112938. PubMed ID: 33109398
[TBL] [Abstract][Full Text] [Related]
10. Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells.
Moutouh-de Parseval LA; Verhelle D; Glezer E; Jensen-Pergakes K; Ferguson GD; Corral LG; Morris CL; Muller G; Brady H; Chan K
J Clin Invest; 2008 Jan; 118(1):248-58. PubMed ID: 18064299
[TBL] [Abstract][Full Text] [Related]
11. Cilostazol-mediated reversion of γ-globin silencing is associated with a high level of HbF production: A potential therapeutic candidate for β-globin disorders.
Ali H; Khan F; Musharraf SG
Biomed Pharmacother; 2021 Oct; 142():112058. PubMed ID: 34426256
[TBL] [Abstract][Full Text] [Related]
12. Effect of fetal hemoglobin-stimulating medicines on the interaction of DNA and protein of important erythroid regulatory elements.
Ji XJ; Liu DP; Xu DD; Li L; Liang CC
Biochem Cell Biol; 2003 Aug; 81(4):297-305. PubMed ID: 14569302
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological and molecular approaches for the treatment of β-hemoglobin disorders.
Lohani N; Bhargava N; Munshi A; Ramalingam S
J Cell Physiol; 2018 Jun; 233(6):4563-4577. PubMed ID: 29159826
[TBL] [Abstract][Full Text] [Related]
14. Hemoglobin switching's surprise: the versatile transcription factor BCL11A is a master repressor of fetal hemoglobin.
Bauer DE; Orkin SH
Curr Opin Genet Dev; 2015 Aug; 33():62-70. PubMed ID: 26375765
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic regulation of fetal globin gene expression in adult erythroid cells.
Ginder GD
Transl Res; 2015 Jan; 165(1):115-25. PubMed ID: 24880147
[TBL] [Abstract][Full Text] [Related]
16. Induction of fetal globin in beta-thalassemia: Cellular obstacles and molecular progress.
Perrine SP; Castaneda SA; Boosalis MS; White GL; Jones BM; Bohacek R
Ann N Y Acad Sci; 2005; 1054():257-65. PubMed ID: 16339673
[TBL] [Abstract][Full Text] [Related]
17. Lysine-specific demethylase 1 is a therapeutic target for fetal hemoglobin induction.
Shi L; Cui S; Engel JD; Tanabe O
Nat Med; 2013 Mar; 19(3):291-4. PubMed ID: 23416702
[TBL] [Abstract][Full Text] [Related]
18. When basic science reaches into rational therapeutic design: from historical to novel leads for the treatment of β-globinopathies.
Andrieu-Soler C; Soler E
Curr Opin Hematol; 2020 May; 27(3):141-148. PubMed ID: 32167946
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic hemoglobin levels after gene transfer in β-thalassemia mice and in hematopoietic cells of β-thalassemia and sickle cells disease patients.
Breda L; Casu C; Gardenghi S; Bianchi N; Cartegni L; Narla M; Yazdanbakhsh K; Musso M; Manwani D; Little J; Gardner LB; Kleinert DA; Prus E; Fibach E; Grady RW; Giardina PJ; Gambari R; Rivella S
PLoS One; 2012; 7(3):e32345. PubMed ID: 22479321
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Rapamycin as Inducer of Hb F in Primary Erythroid Cultures from Sickle Cell Disease and β-Thalassemia Patients.
Pecoraro A; Troia A; Calzolari R; Scazzone C; Rigano P; Martorana A; Sacco M; Maggio A; Di Marzo R
Hemoglobin; 2015; 39(4):225-9. PubMed ID: 26016899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
